ÂÜÀòÂÒÂ×

Patrick joined TRIANA Biomedicines in December of 2021 as CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the company’s CSO. As member of Constellation’s executive team Patrick materially contributed to several successful financing rounds and deals, including a $100M crossover round, a $65M IPO and the ultimate acqusition of Constellation in 2021 for $1.7b. Patrick‘s entrapreneurial mindset resulted in his co-founding of Constellation Pharmaceuticals in 2008. Patrick was instrumental to build Constellation‘s discovery platform, established a portfolio of competitive clinical candidates and drove the maturation of the company‘s development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. Prior to his industrial career he was a Postdoctoral Fellow at NYU, Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape (epigenetics) on processes that require access to DNA, including the regulation of gene expression. Patrick received his Ph.D. in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria.